Phase 2b Trial of a NaV1.8 Inhibitor for Acute Pain
New England Journal of Medicine, Volume 395, Issue 5, Page 454-464, July 30, 2026.
We haven't written up this one. NEJM has the full story — the link below goes straight to it.
More in Health & Medicine
Uninsured but Undaunted, a Surgical Patient Searched the Globe for a Deal
When surgery became unavoidable, a man with no insurance shopped around for the best price for a hernia repair — and saved thousands by traveling out of state.
Trump Has Quietly Throttled an Agency Devoted to the Safety of American Healthcare
Congress appropriated $345 million for the Agency for Healthcare Research and Quality for the 2026 fiscal year, but the agency has spent less than $15 million on grants.
Hospice’s Bad Reputation Amid Fraud Crisis Will Hurt Patients, Industry Experts Warn
While acknowledging that changes must be made to the hospice industry, health policy researchers and providers worry that negative attention and the potential for overly punitive regulations could put…
iEvac-Z, an Inactivated Ebola Vaccine — Phase 1 Study in Japan
New England Journal of Medicine, Volume 395, Issue 7, Page 715-717, August 13, 2026.
Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials
Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has raised $20…
Op-Ed: Hepatitis Is the Test of Africa’s Health Sovereignty
Health-e News Op-Ed: Hepatitis Is the Test of Africa’s Health Sovereignty This week, Africa Centres for Disease Control and Prevention (Africa CDC) released the Operational Toolkit for the Prevention…